ENTITY

Dogwood Therapeutics (DWTX US)

4
Analysis
Health CareUnited States
Dogwood Therapeutics, Inc. operates as a development-stage biotechnology. The Company develops novel therapeutics and sodium channel blocker to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications. Dogwood Therapeutics serves patients in the United States.
more
12 Nov 2024 03:00Issuer-paid

DWTX: Phase 2 Long COVID Results Expected Soon

On November 7, 2024, Dogwood Therapeutics, Inc. (DWTX) announced financial results for the third quarter of 2024 and provided a business...

Share
16 Oct 2024 09:40Issuer-paid

Dogwood Therapeutics, Inc. - DWTX: Virios Therapeutics Becomes Dogwood Therapeutics

On October 7, 2024, Virios Therapeutics, Inc. (VIRI) announced a business combination with privately-held Wex Pharmaceuticals, Inc. to form Dogwood...

Share
14 Aug 2024 00:00Issuer-paid

VIRI: Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024

On August 8, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the second quarter of 2024 and provided a business update. The...

Share
14 May 2024 00:00Issuer-paid

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update. The...

Share
x